Potential Use of Nitrogen-Doped Carbon Nanotube Sponges as Payload Carriers Against Malignant Glioma

Salazar, Alelí; Cruz, Verónica Pérez-De La; Muñoz‐Sandoval, Emilio; Chavarria, Víctor; Morales, María de Lourdes García; Espinosa-Bonilla, Alejandra; Sotelo, Julio; Jiménez-Anguiano, Anabel; Pineda, Benjamín

doi:10.3390/nano11051244

Cited by 17 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results showed that N-CNSs, at concentrations below 40 μg/mL, did not exhibit significant cytotoxic effects. Carmustine-loaded N-CNSs were able to continuously release carmustine up to 72 h from initial administration, with adverse effects comparable to that of carmustine alone [ 132 ]. Figure 3 illustrates CDs as theranostic agents in cancer [ 127 ].…”

Section: Inorganic Nanoparticlesmentioning

confidence: 99%

New insights into targeted therapy of glioblastoma using smart nanoparticles

Ghaznavi,

Afzalipour,

Khoei

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

In recent times, the intersection of nanotechnology and biomedical research has given rise to nanobiomedicine, a captivating realm that holds immense promise for revolutionizing diagnostic and therapeutic approaches in the field of cancer. This innovative fusion of biology, medicine, and nanotechnology aims to create diagnostic and therapeutic agents with enhanced safety and efficacy, particularly in the realm of theranostics for various malignancies. Diverse inorganic, organic, and hybrid organic–inorganic nanoparticles, each possessing unique properties, have been introduced into this domain. This review seeks to highlight the latest strides in targeted glioblastoma therapy by focusing on the application of inorganic smart nanoparticles. Beyond exploring the general role of nanotechnology in medical applications, this review delves into groundbreaking strategies for glioblastoma treatment, showcasing the potential of smart nanoparticles through in vitro studies, in vivo investigations, and ongoing clinical trials.

show abstract

Section: Inorganic Nanoparticlesmentioning

confidence: 99%

New insights into targeted therapy of glioblastoma using smart nanoparticles

Ghaznavi,

Afzalipour,

Khoei

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…Salazar et al developed a CNT that carries carmustine for testing in malignant glioma cell lines. The carbon nanotubes loaded with carmustine showed a continuous kinetic release of the drug, with a maximal release at 72 h. This contributed to increased intratumoral drug concentration, less systemic toxicity, and equivalent normal brain cytotoxicity when compared to the free drug [ 48 ].…”

Section: Types Of Nanoparticlesmentioning

confidence: 99%

Nanoparticle-Based Treatment in Glioblastoma

Roque,

Cruz,

Ferreira

et al. 2023

JPM

View full text Add to dashboard Cite

Glioblastoma (GB) is a malignant glioma associated with a mean overall survival of 12 to 18 months, even with optimal treatment, due to its high relapse rate and treatment resistance. The standardized first-line treatment consists of surgery, which allows for diagnosis and cytoreduction, followed by stereotactic fractionated radiotherapy and chemotherapy. Treatment failure can result from the poor passage of drugs through the blood–brain barrier (BBB). The development of novel and more effective therapeutic approaches is paramount to increasing the life expectancy of GB patients. Nanoparticle-based treatments include epitopes that are designed to interact with specialized transport systems, ultimately allowing the crossing of the BBB, increasing therapeutic efficacy, and reducing systemic toxicity and drug degradation. Polymeric nanoparticles have shown promising results in terms of precisely directing drugs to the brain with minimal systemic side effects. Various methods of drug delivery that pass through the BBB, such as the stereotactic injection of nanoparticles, are being actively tested in vitro and in vivo in animal models. A significant variety of pre-clinical studies with polymeric nanoparticles for the treatment of GB are being conducted, with only a few nanoparticle-based drug delivery systems to date having entered clinical trials. Pre-clinical studies are key to testing the safety and efficacy of these novel anticancer therapies and will hopefully facilitate the testing of the clinical validity of this promising treatment method. Here we review the recent literature concerning the most frequently reported types of nanoparticles for the treatment of GB.

show abstract

“…There were no morphological alterations, merely a minor dot pattern within the cells. 233 Lu et al combined MW-CNTs and IONPs with DOX to achieve effective drug delivery for GBM therapy. MW-CNTs were functionalized with poly(acrylic acid) via the free radical polymerization method, and then fabricated with MNs and conjugated with folic acid for DOX loading.…”

Section: Reviewmentioning

confidence: 99%